HomeCONGRESS

CONGRESS

J- REVERSE: sirolimus-eluting vs. everolimus-eluting stent in bifurcation lesions

Asymmetrical expansion of the stent produces an uneven neointimal growth and increases the risk of thrombosis. The...

ORBIT II: new atherectomy device

The objective of the study was to test the use of a new atherectomy device to prepare...

DEFLECT I: cerebral protection device in TAVI

Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being...

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve...

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device...

PROTAVI-C: Embolic protection during TAVI

Percutaneous aortic valve replacement (TAVI) is a new treatment option for patients that are inoperable or present...

EXPAND: expanding the applications of bioresorbable platforms

There is little information about the use of bioresorbable vascular devices in patients with a reference diameter...

BuMA stent: new sirolimus-eluting stent with bio-degradable polymer

Uncovered struts compromise re-endothelization and may induce thrombosis. The new stent approved in China and already used...